Drug intelligence / Profile preview

hPMSCsPRL-1

Development stage: Unknown
Modality: Stem Cell Therapies → Cell Therapies

Overview

Based on nomenclature analysis, this appears to be a functionally enhanced human placenta-derived mesenchymal stem cell therapy, potentially modified or selected for PRL-1 expression or function. However, specific information about this therapeutic candidate is not available in the provided sources.

Beyond the preview

Go deeper on hPMSCsPRL-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hPMSCsPRL-1.

Explore the full profile